ISN Medical eyes African expansion, local manufacturing

ISN Medical has stated that it is positioning itself for deeper expansion across Africa while exploring local manufacturing of medical products in Nigeria.

Managing Director and Chief Executive Officer of ISN Medical, Felix Ofungwu, disclosed this during a hybrid media briefing in Lagos, where he described Nigeria’s healthcare market as one of the most challenging environments to operate in due to low health insurance coverage and high out-of-pocket spending by patients.

He said that, unlike countries such as Rwanda and the United Kingdom, where healthcare systems are more structured, most Nigerians still pay directly for healthcare services, making the sector highly price-sensitive.

“The Nigerian healthcare market is complex. More than 90 per cent of patients still pay out of pocket for treatment, and that creates pressure on healthcare providers and patients alike,” Ofungwu said.

He stated that the company operates with internationally recognised standards, including ISO 9001 and ISO 13485 certifications, which distinguish it within the healthcare industry.

He added that the company mainly supplies diagnostic equipment, reagents, and consumables used in laboratories and hospitals to confirm medical diagnoses.

“One of the products we are well known for is Accu-Chek, used by people living with diabetes to monitor blood sugar levels. We also provide test kits for malaria and other diseases,” Ofungwu said.

He stated that the company also supports disease research laboratories and operates a subsidiary focused on chronic illness management for patients living with diabetes, hypertension, and kidney disease.

“We have in-house engineers trained to maintain and repair every piece of equipment we supply. We also train healthcare professionals on how to properly use these systems,” Ofungwu said.

Speaking on the company’s Life Sciences operations, Ofungwu said ISN Medical was delivering advanced genomic sequencing solutions, including paternity testing services, as part of efforts to expand beyond diagnostics into personalised medicine.